Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Rate of New Premium for New Drug Development Will Be 5.10%
January 25, 2010
- Eisai to Apply for Eribulin in Japan, the US and Europe in March
January 25, 2010
- 61% of Drug Companies Welcome New Pricing System: Questionnaire
January 25, 2010
- MK-8669 Enters PII in Japan: Banyu
January 25, 2010
- Panel of Experts on Unapproved Drugs/Indications to Be Inaugurated
January 25, 2010
- MBL, Osaka Univ. Isolate Fully-Human Flu Virus MAB
January 25, 2010
- Companies Should Be Encouraged to Participate in New Growth Strategy: Mr Nagatsuma
January 25, 2010
- Tasigna Shown to Be Superior to Glivec for CML: Novartis
January 25, 2010
- Eisai Applies for Pediatric Indication for lecainide Based on Data in Public Domain
January 25, 2010
- Abbott's Everolimus-Eluting Stent XIENCE V Approved in Japan
January 25, 2010
- Anti-Flu Agent Rapiacta Approved: Shionogi
January 25, 2010
- Seikagaku Receives Not-Approvable Letter for Gel-200 from FDA
January 25, 2010
- Flu Vaccines from GSK, Novartis Receive First “Emergency Approval”
January 25, 2010
- Kobayashi Aims at \4.5 Bil. with New Products in FY2010
January 25, 2010
- Sales of Crestor in Japan to Exceed ¥100 Bil.
January 25, 2010
- New Subcommittee to Be Created for Regulatory Reform
January 25, 2010
- GLs for Ads on Illegal Drugs on Internet to Be Revised
January 25, 2010
- Informed Consent Not Obtained from Many Recipients of Albumin Products
January 25, 2010
- NCs to Take Over Part of Long-Term Debt
January 25, 2010
- Gov't New Growth Strategy to Stimulate Market for OTC Drugs: Mr Hatori
January 25, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…